MDisrupt Webinar Panel: Kevin Coker, Proxima Clinical Research's CEO, In a Panel Discussing, "How will regulation of digital health products be impacted with the new administration?"

‍

‍

With the transition to the Biden-Harris Administration, appointing new leadership within the healthcare focused agencies, and the swearing in of the new Congress, the precision medicine industry can expect new attention to critical policy issues including regulation of diagnostic testing, digital health platforms, and at home testing. Is your regulatory team prepared for these changes?

In this webinar, we will cover:

• What are the priorities of the incoming administration and new Congress?
• How will these priorities shift the way the FDA is thinking about regulating     laboratory developed tests and digital health software?
• How should regulatory teams in health tech companies start to prepare for these shifts?
• How will your legal team be thinking about recently implemented regulations during and after the transition?

Access the webinar, here.